Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Luminex Corporation
Type
Corporation
Traded as NASDAQ: LMNX
S&P 600 Component
Industry Biotechnology
Founded 1995
Headquarters Austin, Texas, United States,
Products xMAP, xTAG, MAGPIX, Luminex 100/200, FLEXMAP 3D, NxTAG, ARIES
Website Luminexcorp.com

Luminex Corporation is a biotechnology company based in Austin, Texas, with offices in Madison, Wisconsin, Chicago, Illinois, Toronto, the Netherlands, Shanghai and Tokyo. Luminex develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences. Nachum "Homi" Shamir has served as Luminex's President and Chief Executive Officer since October, 2014. Luminex was recognized by Forbes magazine as one of the top 25 fastest growing technology companies in the US.

Luminex's (Multi-Analyte Profiling (xMAP) technology allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. xMAP technology is currently being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. Luminex MultiCode technology, used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays.

Luminex Corporation owns 315 issued patents worldwide, including over 124 issued patents in the United States based on its multiplexing xMAP platform. Luminex's proprietary multiplex bead-based immunoassay testing platform simultaneously measures multiple analytes by exciting a sample with a laser, and subsequently analyzing the wavelength of emitted light. Luminex's MAGPIX platform utilizes LED technology and digital photography to analyze,"color-coded magnetic microspheres". In 2008 Luminex received FDA 510(k) clearance for its xTAG Respiratory Viral Panel which allows doctors to test for the presence of 12 respiratory viruses with a very high degree of accuracy in a matter of hours, and has been proven to provide an increase in accuracy over in-house nucleic acid amplification testing in the diagnosis of respiratory virus infections. Luminex's xTAG Gastrointestinal Pathogen Panel was granted a CE mark by the European Union in 2012 and received FDA and Health Canada clearance in early 2013. Luminex also has an extensive portfolio of genetics assays focused on cystic fibrosis and pharmacogenetics.

In 2010 Luminex Corporation received the Prix Galien USA award. In 2011 Luminex Corporation's MAGPIX multiplexing bioassay platform received the Medical Design Excellence Award.

Investment goal date:
Dividends reinvested
Luminex Corporation LMNX report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-02
--
--
Q4 2017
2018-02-05
--
--
Q3 2017
2017-10-30
0.1200
0.4000
Q2 2017
2017-08-07
0.1300
0.1300
Q1 2017
2017-05-01
0.2100
0.2100
Q4 2016
2017-02-06
-0.0800
-0.0800
Q3 2016
2016-10-31
0.0600
0.0600
Q2 2016
2016-07-28
0.1300
0.1300
Q1 2016
2016-05-02
0.2100
0.2100
Q4 2015
2016-02-01
0.4700
0.4700
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
1158290
Bank of New York Mellon Corp
660135
BlackRock Fund Advisors
3694943
BlackRock Inc.
5063064
BlackRock Institutional Trust Company, N.A.
1059432
DIMENSIONAL FUND ADVISORS LP
1718886
Elk Creek Partners, LLC
698416
INVESTMENT MANAGEMENT OF VIRGINIA LLC
868953
Neuberger Berman Group LLC
968464
NORTHERN TRUST CORP
500451
RENAISSANCE TECHNOLOGIES LLC
1589241
RGM Capital, LLC
2715517
STATE STREET CORP
1009789
Vanguard Group, Inc
3446060
VILLERE ST DENIS J & CO LLC
3813623
Major Shareholders
Name Relationship
Total Shares
Holding stocks
KEVER JIM D
0.5000% (213800)
DDD / LMNX / TSN /
LOEWENBAUM G WALTER II
1.6700% (713896)
DDD / LMNX /
ERICKSON THOMAS W
0.3800% (162221)
ARA / DDD / LMNX /
DEHNE TIMOTHY R
0.0500% (20441)
CRUS / LMNX /
CRESCI ROBERT J
0.5000% (215800)
CMCT / JCOM / LMNX /
MCNAMARA KEVIN M
0.1700% (73503)
LMNX / TSN /
GOAD FRED C JR
0.6700% (287957)
EMAG / LMNX /
CURRIE HARRISS T
0.4400% (188336)
LMNX /
REITER DAVID S
0.1400% (60400)
LMNX /
BALTHROP PATRICK J
1.1400% (486367)
LMNX / OXFD /
OGUNRO EDWARD A
0.1000% (44147)
LMNX /
Johnston Jay B
0.3200% (138696)
LMNX /
Bradley Russell W
0.2400% (100667)
LMNX /
BRIDGE-COOK JEREMY K
0.1700% (74273)
LMNX /
Rew Richard W. II
0.0200% (8465)
ARTC / LMNX /
PINTEK MICHAEL F
0.1400% (59234)
LMNX /
SHAMIR NACHUM
0.2900% (123503)
LMNX / VSCI /
Fairchild Nancy
0.0900% (36563)
LMNX /
Myers Randall
0.0200% (6634)
LMNX /
Eck Stephen L.
0.0300% (14614)
LMNX /
Lazarus Tadd S.
0.0200% (10495)
LMNX /
% ()